Group 1 - The company conducted a research meeting from June 9 to June 11, 2025, focusing on its operational performance and market conditions [1] - In the first five months of 2025, the heavy truck market in China saw cumulative sales of approximately 437,500 units, a slight year-on-year increase of about 1%. In May alone, sales reached around 85,000 units, reflecting a year-on-year growth of approximately 9% [2] - The company reported that its production and sales performance remained strong, with growth compared to the same period last year, outperforming the industry average [2] Group 2 - The new "old-for-new" policy introduced in March 2025, which includes subsidies for scrapping and purchasing new natural gas heavy trucks, is expected to accelerate the replacement of old vehicles and promote the transition towards greener and more efficient technologies in the industry [2] - The company plans to leverage policy opportunities to enhance technological innovation and market expansion, aiming for high-quality business development [2] Group 3 - In the first five months of 2025, cumulative sales of new energy heavy trucks in China reached 51,000 units, representing a significant year-on-year increase of 195%. The industry is currently experiencing rapid growth driven by policy support and technological advancements [2] - The company is committed to deepening its focus on the new energy sector, promoting product innovation and application in various scenarios to enhance product advantages and market share [2]

Group 1: Company Overview - In 2024, the company's revenue was 749.5 million, representing a year-on-year growth of 10.53% [2] - The net profit attributable to shareholders was 20.1 million, showing a year-on-year decline of 63.68% [2] - The net profit after deducting non-recurring gains and losses was -6.2861 million, a year-on-year decrease of 114.13% [2] Group 2: Financial Metrics - Total sales expenses for the year amounted to 250 million, while research and development expenses were 164 million [2] - The company's gross margin was affected by the adoption of new accounting standards and an increase in overseas revenue, which generally has a lower gross margin compared to domestic operations [2] Group 3: Business Strategy and Market Position - The company aims to become a globally influential endoscope brand by enhancing product performance and brand recognition [2] - The overseas business is still in the early stages of development, with a diverse product mix and a higher proportion of low-to-mid-priced products, leading to lower gross margins compared to domestic operations [2] - The company is actively expanding its overseas market presence, particularly in Europe and other cost-effective markets, where there is incremental demand for soft endoscopes [2] Group 4: Industry Insights - The importance of endoscopic diagnosis is emphasized, as early screening of the digestive tract can significantly improve patient survival rates and quality of life [2] - The clinical demand for respiratory endoscopy is gradually emerging, with the company planning to track developments in this area closely [2]

Core Viewpoint - The company is actively advancing its clinical research and product pipeline in the field of chronic hepatitis B treatment, particularly focusing on the approval and market penetration of its drug, Paigebin, and its combination therapies [2][3]. Group 1: Clinical Developments - The latest approval timeline for the clinical cure indication for chronic hepatitis B is expected to be submitted to the National Medical Products Administration in March 2024, currently under technical review [2]. - The establishment of clinical cure outpatient clinics is ongoing, which is anticipated to positively impact sales by enhancing treatment standardization and increasing patient awareness [2]. - The company is also progressing with the registration application for its growth hormone product, which was accepted in January 2024 and is currently under technical review [2]. Group 2: Research and Development Strategy - The company plans to increase R&D investment in line with clinical needs, focusing on immunology and metabolism, with an upward trend in overall R&D spending as more projects enter clinical research [2][3]. - The company has established collaborations for various products, including ongoing preclinical studies and Phase I clinical trials, indicating a robust pipeline in liver disease and gene therapy [2][3]. Group 3: Market Insights and Future Outlook - The penetration rate of long-acting interferon in chronic hepatitis B treatment remains low, but the company believes that new therapies and combination strategies will increase the patient population receiving antiviral treatment [3]. - The company anticipates that the market for long-acting interferon will expand as new drugs for hepatitis B are launched, supported by evidence showing interferon’s effectiveness in reducing liver cancer risk [3]. - The company is exploring various real-world research projects to optimize hepatitis B treatment strategies, aiming to broaden the definition and scope of clinical cure populations [3].